Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06680115

Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma

To evaluate the efficacy and safety of neoadjuvant and adjuvant Sintilimab combined with chemoradiotherapy versus chemoradiotherapy alone in stage TanyN3M0 nasopharyngeal carcinoma. The primary endpoint was 2-year failure-free survival (FFS). Secondary endpoints included 2-year overall survival (OS), distant failure-free survival (DFFS), locoregional failure-free survival (LRFFS), and adverse events.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

The First Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi, 530021, China

Location contact

Rensheng Wang

CONTACT

[email protected]

86+0771-5356509

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma;
  • Age≥18 years;
  • Staging TanyN3M0 (AJCC/UICC 9th edition) ;
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
  • White blood cell≥3.5×10^9/L,Neutrophils≥1.5×10^9/L, hemoglobin≥ 90 g/L, platelet (PLT)≥ 100x10^9/ L ;
  • Transaminases≤2.5 times the upper limit of normal, total bilirubin <1.5 times the upper limit of normal;
  • Creatinine clearance ≥60 ml/min;
  • Signed informed consent form.

Exclusion criteria

  • HBsAg positive and HBV DNA >1×103 copy/ml;
  • Patients with positive HCV antibody test results;
  • Active, known, or suspected autoimmune disease. Participants with type 1 diabetes, hypothyroidism requiring hormone replacement therapy, and skin conditions that do not require systemic treatment, such as vitiligo, psoriasis, or hair loss, may be enrolled;
  • History of interstitial lung disease;
  • Received systemic sex hormone or other immunosuppressive therapy with equivalent dose > 10mg prednisone/day within 28 days before signing the informed consent. Participants with a systemic sex hormone dose ≤10mg prednisone/day or inhaled/topical corticosteroids were enrolled;
  • Have received or will receive live vaccine within 30 days before signing the informed consent;
  • Pregnant or lactating women (pregnancy tests should be considered for sexually active, fertile women);
  • Had other malignancies within 5 years, except carcinoma in situ, adequately treated non-melanoma skin cancer, and papillary thyroid cancer;
  • The subject is known to have a prior allergy to macromolecular protein preparations, or any of the components of sindillizumab;
  • Human immunodeficiency virus (HIV) infection;
  • Other conditions, as determined by the investigator, that may affect subjects' safety or compliance with the study include symptomatic heart failure, unstable angina pectoris, myocardial infarction, active infection requiring systemic treatment, mental illness, or family and social factors.

Treatment and study plan

Sintilimab

Drug

Induction chemotherapy stage: Sintilimab combined with GP regimen chemotherapy; Adjuvant chemotherapy stage: Sintilimab combined with Capecitabine

Primary outcomes

  1. Failure-free survival

    Time frame: 2 years

Secondary outcomes

  1. Overall survival

    Time frame: 2 years

  2. Distant failure-free survival

    Time frame: 2 years

  3. Locoregional failure-free survival

    Time frame: 2 years

Study contacts

Contact information is provided by the study sponsor or research team.

Rensheng Wang

CONTACT

[email protected]

86-0771-5356509

Sponsors and collaborators

Lead sponsor

First Affiliated Hospital of Guangxi Medical University

Other

Registry information

Official study title

Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma: a Multicenter, Open-label, Randomized Phase II Clinical Trial

Important dates

Study start
2024
Primary completion
2026
Study completion
2029
First posted
Nov 8, 2024
Registry last updated
Nov 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.